Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Luming Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2311-6546; OpenAlex author ID A5101697640. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers

Papers 17

  1. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Last author DOI 10.1016/j.lfs.2021.119205↗
  2. Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.015↗
  3. miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. Last author DOI 10.2147/ott.s227644↗
  4. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Last author DOI 10.18632/aging.102307↗
  5. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. Last author DOI 10.1177/0300060518800588↗
  6. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Co-author DOI 10.1177/1534735418771193↗
  7. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Co-author PMID 28123853↗
  8. Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Last author DOI 10.1155/2016/7028289↗
  9. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  10. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Last author DOI 10.1038/srep05911↗
  11. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Last author DOI 10.1371/journal.pone.0096177↗
  12. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting… Co-author DOI 10.1016/j.molonc.2012.10.011↗
  13. Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. Last author DOI 10.1371/journal.pone.0070334↗
  14. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Last author DOI 10.1007/s11010-010-0619-y↗
  15. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Last author DOI 10.1097/mpa.0b013e3181e6e398↗
  16. Metastatic adenocarcinoma of the epididymis from pancreatic cancer successfully treated by chemotherapy and high-intensity focused ultrasound therapy: a case r… Last author DOI 10.1097/mpa.0b013e318221816d↗
  17. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Last author DOI 10.3109/02656736.2010.525588↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiqiang Meng · 13 shared papers, 2011–2020 · strength 0.74
  2. Zhen Chen · 11 shared papers, 2011–2019 · strength 0.54
  3. Peng Wang · 8 shared papers, 2011–2018 · strength 0.44
  4. Zhouyu Ning · 4 shared papers, 2016–2021 · strength 0.38
  5. Yongqiang Hua · 4 shared papers, 2016–2021 · strength 0.34
  6. Ye Li · 2 shared papers, 2020–2021 · strength 0.27
  7. Hao Chen · 4 shared papers, 2014–2019 · strength 0.25
  8. Ke Zhang · 2 shared papers, 2019–2021 · strength 0.24
  9. Lanyun Feng · 3 shared papers, 2016–2021 · strength 0.24
  10. Lianyu Chen · 5 shared papers, 2011–2017 · strength 0.22
  11. Weidong Shi · 3 shared papers, 2011–2021 · strength 0.22
  12. Yehua Shen · 2 shared papers, 2016–2020 · strength 0.17
  13. Liping Zhuang · 2 shared papers, 2013–2020 · strength 0.16
  14. Qi Qi · 2 shared papers, 2014–2018 · strength 0.13
  15. Huifeng Gao · 1 shared paper, 2020 · strength 0.13
  16. Gang Chen · 1 shared paper, 2020 · strength 0.13
  17. Chao Qu · 2 shared papers, 2014–2017 · strength 0.11
  18. Simin Qi · 1 shared paper, 2021 · strength 0.11
  19. Libin Song · 1 shared paper, 2021 · strength 0.11
  20. Shengli Li · 1 shared paper, 2021 · strength 0.11
  21. Bo Zhang · 1 shared paper, 2021 · strength 0.11
  22. Jiang‐Jiang Qin · 1 shared paper, 2021 · strength 0.11
  23. Kun Wang · 3 shared papers, 2011–2014 · strength 0.10
  24. Feng-Jiao Wang · 1 shared paper, 2018 · strength 0.09
  25. Yawen Geng · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.